Positive News Sentiment NASDAQ:MLYS Mineralys Therapeutics - MLYS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $14.85 -0.02 (-0.13%) (As of 03/29/2023 12:00 AM ET) Add Compare Share Share Today's Range$14.25▼$15.2550-Day Range N/A52-Week Range$13.52▼$21.98Volume247,536 shsAverage Volume284,418 shsMarket Capitalization$606.73 millionP/E RatioN/ADividend YieldN/APrice Target$36.20 ProfileAnalyst RatingsChartCompetitorsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Mineralys Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside143.8% Upside$36.20 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$25.10 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($3.96) to ($5.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector225th out of 999 stocksPharmaceutical Preparations Industry93rd out of 489 stocks 4.5 Analyst's Opinion Consensus RatingMineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.20, Mineralys Therapeutics has a forecasted upside of 143.8% from its current price of $14.85.Amount of Analyst CoverageMineralys Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MLYS. Previous Next 0.0 Dividend Strength Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLYS. Previous Next 3.8 News and Social Media Coverage News SentimentMineralys Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mineralys Therapeutics this week, compared to 2 articles on an average week.Search Interest32 people have searched for MLYS on MarketBeat in the last 30 days. This is an increase of 256% compared to the previous 30 days.MarketBeat Follows9 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,100,000.00 in company stock and sold $0.00 in company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($3.96) to ($5.36) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Mineralys Therapeutics (NASDAQ:MLYS) StockMineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa.Read More Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Stock News HeadlinesMarch 18, 2023 | finanznachrichten.deMineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 18, 2023 | markets.businessinsider.comCredit Suisse Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)March 29, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 16, 2023 | msn.comWhere Mineralys Therapeutics Stands With AnalystsMarch 15, 2023 | finance.yahoo.comMineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 7, 2023 | msn.comMineralys gains as Wells Fargo, Stifel issue bullish ratings citing lead assetMarch 4, 2023 | finance.yahoo.comMineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCCMarch 1, 2023 | finance.yahoo.comMineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023March 29, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 20, 2023 | finance.yahoo.comMineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Company Calendar Today3/29/2023Next Earnings (Estimated)6/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MLYS CUSIPN/A CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$36.20 High Stock Price Forecast$45.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+143.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares40,857,000Free FloatN/AMarket Cap$606.73 million OptionableNot Optionable BetaN/A Key CompetitorsDyne TherapeuticsNASDAQ:DYNRAPT TherapeuticsNASDAQ:RAPTAmarinNASDAQ:AMRNTyra BiosciencesNASDAQ:TYRATheravance BiopharmaNASDAQ:TBPHView All CompetitorsInsidersHbm Healthcare Investments (CaBought 312,500 shares on 2/14/2023Total: $5 M ($16.00/share)Ra Capital Management, L.P.Bought 1,250,000 shares on 2/14/2023Total: $20 M ($16.00/share)Adam Scott LevyBought 6,250 shares on 2/14/2023Total: $100,000.00 ($16.00/share)View All Insider Transactions MLYS Stock - Frequently Asked Questions Should I buy or sell Mineralys Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MLYS shares. View MLYS analyst ratings or view top-rated stocks. What is Mineralys Therapeutics' stock price forecast for 2023? 6 brokers have issued 1-year target prices for Mineralys Therapeutics' stock. Their MLYS share price forecasts range from $27.00 to $45.00. On average, they predict the company's stock price to reach $36.20 in the next twelve months. This suggests a possible upside of 143.8% from the stock's current price. View analysts price targets for MLYS or view top-rated stocks among Wall Street analysts. How have MLYS shares performed in 2023? Mineralys Therapeutics' stock was trading at $18.44 on January 1st, 2023. Since then, MLYS shares have decreased by 19.5% and is now trading at $14.85. View the best growth stocks for 2023 here. When is Mineralys Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 21st 2023. View our MLYS earnings forecast. When did Mineralys Therapeutics IPO? (MLYS) raised $180 million in an initial public offering on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share. What is Mineralys Therapeutics' stock symbol? Mineralys Therapeutics trades on the NASDAQ under the ticker symbol "MLYS." When did the company's quiet period expire? Mineralys Therapeutics' quiet period expired on Wednesday, March 22nd. Mineralys Therapeutics had issued 12,000,000 shares in its public offering on February 10th. The total size of the offering was $192,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mineralys Therapeutics' stock price today? One share of MLYS stock can currently be purchased for approximately $14.85. How much money does Mineralys Therapeutics make? Mineralys Therapeutics (NASDAQ:MLYS) has a market capitalization of $606.73 million. How can I contact Mineralys Therapeutics? The official website for the company is www.mineralystx.com. The company can be reached via phone at 888-378-6240 or via email at investorrelations@mineralystx.com. This page (NASDAQ:MLYS) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.